Get notified when ACTU files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Substantial doubt persists with auditor qualification; current filing specifies July 2026 cash depletion vs generic 12-month language in baseline.
- Material Weakness (removed) — Material weakness in clinical trial expense accruals was remediated as of December 31, 2024 and is no longer disclosed.
Actuate reports positive Phase 2 pancreatic cancer data but flags cash depletion by July 2026
Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 13, 2025 · ~2 min read
Key Changes
-
high
Phase 2 trial met primary endpoint: elraglusib + chemo improved median survival to 10.1 months vs 7.2 months for chemo alone (p=0.02), with 12-month survival nearly doubling to 44.4% vs 22.3%.
Business: Phase 2 mPDAC trial results verify on EDGAR → -
high
Company disclosed substantial doubt about going concern with cash runway ending July 2026—approximately 3-4 months from filing date. Accumulated deficit grew $22M to $154.6M.
MD&A: Going concern & cash runway verify on EDGAR → -
high
Three capital raises during 2025 totaled ~$24M gross ($3.8M equity line, $4.6M private placement, $15.6M public offering at $7/share), bringing year-end cash to $13.2M vs $8.6M prior year.
MD&A: Capital raises verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade ACTU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify